Dichotomous effect of methylphenidate on microglia and astrocytes: Insights from in vitro and animal studies

Toxicol Lett. 2023 Nov 1:389:1-10. doi: 10.1016/j.toxlet.2023.10.008. Epub 2023 Oct 14.

Abstract

Methylphenidate (MPH) has been used for decades to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. Moreover, several studies have shown that it is subject to misuse, particularly among college students and adolescents, for cognitive enhancement or as a recreational drug. This phenomenon causes concern, and it is critical to clarify better how MPH impacts brain cells. In fact, data has suggested that MPH could result in neuroinflammation and neurodegeneration across several brain regions; however, little is known about the effect of MPH on glial cells. To address this, we used microglia N9 cell line and primary cultures of cortical astrocytes that were exposed to MPH (0.01 - 2 mM), as well as Wistar Kyoto rats (WKY) chronically administered with MPH (1.5 mg/kg/day). Several parameters were analyzed, and we concluded that MPH has no significant direct effect on microglial cells, apart from cell migration impairment. On the contrary, MPH promotes astrogliosis, oxidative/nitrosative stress, and increases proinflammatory cytokine TNF levels by astrocytes, which was concordant with the results obtained in the hippocampus of WKY rats. Overall, the present results suggest that brain cells respond differently to MPH, with a more prominent direct effect on astrocytes when compared to microglia.

Keywords: Astrocytes; Hippocampus; Inflammatory mediators; Methylphenidate; Microglia; Oxidative stress.

MeSH terms

  • Adolescent
  • Animals
  • Astrocytes
  • Attention Deficit Disorder with Hyperactivity*
  • Central Nervous System Stimulants* / toxicity
  • Humans
  • Methylphenidate* / toxicity
  • Microglia
  • Rats
  • Rats, Inbred WKY

Substances

  • Methylphenidate
  • Central Nervous System Stimulants